



Press release,
Malmö, Sweden, 2024-05-21

NOTICE OF ANNUAL GENERAL MEETING IN AXICHEM

The shareholders in aXichem AB (publ) are invited to the Annual General Meeting on Wednesday, June 19, 2024 at 10 a.m. in the company's premises, Södergatan 26, in Malmö.

Right to participate in the Annual General Meeting and notification

Shareholders who wish to participate in the Annual General Meeting must:

1. be entered in the share register prepared by Euroclear Sweden AB regarding the conditions on Tuesday, June 11, 2024, and
2. register for the meeting no later than Thursday, June 13, 2024. Notification must be made by post to aXichem AB (publ), Södergatan 26, 211 34 Malmö, Sweden, indicating "Annual General Meeting". Registration can also be done by e-mail to post@axichem.se. The notification must state the name, personal or corporate registration number, number of shares, address, daytime telephone number and, where applicable, the number of any accompanying assistants (maximum two) who are intended to be brought to the meeting.

Nominee-registered shares

To be entitled to participate in the Annual General Meeting, a shareholder whose shares are held in the name of a nominee must, in addition to providing notification of participation, register its shares in its own name so that the shareholder is recorded in the share register relating to the circumstances on Tuesday, June 11, 2024. Such registration may be temporary (so-called voting right registration) and is requested from the nominee according to the nominee's routines at such a time in advance as the nominee determines. Voting right registrations completed by the nominee no later than Thursday, June 13, 2024 are taken into account when preparing the share register.

In aXichem there are 40,305,615 shares and votes. The company does not hold any own shares.

Proxy, etc.

If a shareholder is represented by proxy, a written and dated proxy must be issued. If the proxy is issued by a legal entity, a certificate of registration or equivalent certificate of authority must be enclosed. Proxy forms are provided on the company's website www.axichem.com and are sent free of charge to shareholders who request it and state their postal address. To facilitate registration at the meeting, the proxy, certificate of registration and other certificates of authority should be sent to the company, as set out above, so that it is received no later than Tuesday, June 18, 2024.

Proposal for the agenda

1. Opening of the Annual General Meeting
2. Election of chairman at the Annual General Meeting
3. Election of one or two persons who shall approve the minutes
4. Preparation and approval of the voting list
5. Approval of the agenda
6. Determination of whether the Annual General Meeting has been duly convened
7. Presentation of the annual report and the auditor's report as well as the consolidated accounts and the auditor's report on the consolidated financial statements
8. Resolution regarding:
 - a. adoption of the income statement and balance sheet as well as the consolidated income statement and consolidated balance sheet,
 - b. allocation of the company's results pursuant to the adopted balance sheet, and
 - c. discharge of liability for the Board members and the CEO
9. Resolution regarding the number of Board members and deputy Board members and the number of auditors
10. Resolution regarding the fees to the Board and auditor
11. Election of Board members, Chairman of the Board and auditor
12. Resolution regarding the nomination committee
13. The Board's proposal for a resolution regarding authorization for new issuance of shares
14. Closing of the Annual General Meeting

Resolution proposal

Allocation of the company's result (item 8b)

The Board and the CEO propose that no dividend be paid and that the result for the financial year 2023 be carried forward.

Board etc. (items 2 and 9–12)

The nomination committee's proposal will be presented in good time before the Annual General Meeting.

Issue authorization (item 13)

The Board proposes that the Annual General Meeting resolves to authorize the Board to, at the latest until the time of the next Annual General Meeting, on one or more occasions and with or without pre-emptive rights for the shareholders, resolve on the issue of new shares, convertibles and/or warrants, however that such issue shall not entail that the company's share capital exceeds the company's maximum permitted share capital according to the Articles of Association. Such resolution shall also be possible to make with a provision for in-kind payment, set-off payment or other conditions.

The purpose of the authorization is to increase the company's financial flexibility and the Board's room for action, as well as to potentially expand the company's shareholder base.

Other information

The annual report and all other documentation for resolutions are presented by making them available on the company's website, www.axichem.com, and at the company's office no later than three weeks before the meeting. Copies of the documents are sent to shareholders who request it and state their postal address. The Annual General Meeting share register is also kept available at the company. The shareholders are reminded of their right to request information according to Chapter 7 Section 32 of the Swedish Companies Act.

Processing of personal data

For information on how your personal data is processed go to <https://www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf>. aXichem AB (publ) has organization number 556739-8663 and is located in Lund.

Lund in May 2024
aXichem AB (publ)
The Board of Directors

The information was submitted, through the agency of the contact person, for publication on May 21, 2024, at 09:00 AM CET.

For further information:

Torsten Helsing, CEO, aXichem AB, phone: +46 706 863 355, email: torsten.helsing@axichem.com

About aXichem

aXichem develops, patents and markets natural analogue industrial chemicals, i.e., synthetically produced substances that have similar and comparable properties to natural substances. The company's first product is phenylcapsaicin, which the company commercializes under two brands, aXiphen® and aXivite®, as an ingredient in animal feed and dietary supplements, respectively. The business is divided into three market areas with different applications for phenylcapsaicin: as an ingredient in feed for poultry, such as chicken and turkey; as an ingredient in food supplements for gut health, weight control and sports and exercise; and as an ingredient in food supplements for the bio-enhancement of curcumin and melatonin. aXichem is listed on the Nasdaq First North Growth Market. More information is available at www.axichem.com.